Hepatitis C Treatment: Study Finds No Liver, Kidney or Cardiovascular Adverse Effects

Interview mentions that an ISMP QuarterWatch^TM report raising questions about whether direct acting antiviral medications for the treatment of Hepatitis C posed any significant safety risks for patients was the impetus for further study.

For the full text, visit MedicalResearch.com online.